Don't forget the Australian trial, which proved efficacy at the 84 day endpoint, was only a 4 ml injection. The just ended trial in the US consisted of 4 ml & 10 ml injections. If 4ml injections had some efficacy in Australia, it would stand to reason that the 10 ml injections may have a more pronounced effect.
AMPE enrolled 100 patients, but only showed a statistically significant difference from saline in 30 patients, according their investor presentation. What's the result when all patients are included in the analysis? Why won't AMPE clearly show that the whole dataset is?